Form 4: PharmaCyte Biotech Director Wayne Walker Acquires Stock Options

Director Wayne Walker acquired 38,009 stock options in PharmaCyte Biotech on April 30, 2024, vesting upon the next annual meeting of stockholders.

Summary

• Wayne Walker, a director of PharmaCyte Biotech, acquired 38,009 stock options on April 30, 2024.
• The exercise price of these options is $2.12.
• The options vest in full on the date of the Issuer's next annual meeting of stockholders, contingent upon Mr. Walker's continued service.
• The expiration date for these options is April 30, 2034.
• The reporting of this transaction was late due to an inadvertent administrative error.

Sentiment

Score: 6

Explanation: Neutral sentiment as it reports a standard stock option grant to a director, with a minor negative aspect of a delayed filing due to an administrative error.

Negatives

• The transaction was reported late due to an administrative error.

Future Outlook

The options vest upon the next annual meeting of stockholders, subject to continued service.

Management Comments

• The transaction is late due to an inadvertent administrative error and not any error of Mr. Walker.

Industry Context

This is a standard Form 4 filing, reflecting a director's acquisition of stock options, a common form of executive compensation in publicly traded companies.

Stakeholder Impact

• The acquisition of stock options by a director can be seen as a positive sign by shareholders, aligning management's interests with theirs.

Key Dates

Keywords

stock options, Form 4, director, PMCB, PharmaCyte Biotech, Wayne Walker, acquisition